MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1159/000544979

Медицинская библиотека · Oncology · 2025

Cachexia Index as a Prognostic Indicator in Patients with Unresectable Hepatocellular Carcinoma Receiving Atezolizumab and Bevacizumab Therapy.

Nguyen Khanh Van, Matsui Kosuke, Kosaka Hisashi, Matsushima Hideyuki, Yamamoto Hidekazu, Lai Tung Thanh, Inoue Kyoko, Takada Moriyasu, Tada Fujimasa, Hiraoka Atsushi, Hatanaka Takeshi, Tada Toshifumi, Kumada Takashi, Kato Hiroki, Yoshii Kengo, Yamaguchi Takashi, Shimoda Shinji, Naganuma Makoto, Kaibori Masaki

СтатьяПеревод в очереди

Аннотация

INTRODUCTION

We investigated the association between the pretreatment cachexia index (CXI) and survival outcomes in patients with unresectable hepatocellular carcinoma (u-HCC) receiving atezolizumab plus bevacizumab (Atez/Bev).

METHODS

We conducted a retrospective analysis of 195 patients with u-HCC treated with Atez/Bev from September 2020 to December 2023. The skeletal muscle mass index (SMI) was calculated by normalizing the psoas muscle area by the square of the height (cm2/m2). The CXI was defined as the SMI × serum albumin level (g/dL)/neutrophil-to-lymphocyte ratio. Propensity score matching (PSM) was applied to minimize the effect of potential confounders. Associations between CXI, overall survival (OS), and progression-free survival (PFS) were assessed.

RESULTS

From the initial cohort, CXI cutoffs of 7.23 for males and 4.99 for females were established. PSM matched 60 pairs of patients with low and high CXI, showing no significant differences in confounding factors between groups. Kaplan-Meier analysis indicated that the low CXI group had shorter median OS (12.5 vs. 26.1 months, p = 0.009) and PFS (6.1 vs. 11.1 months, p = 0.045) compared with the high CXI group. No significant differences existed between groups in overall response rate (p = 0.994) and disease control rate (p = 0.090). Multivariate Cox proportional hazards analysis identified low CXI as an independent prognostic factor for OS (HR: 1.89, 95% CI: 1.11-3.22, p = 0.019) and PFS (HR: 1.53, 95% CI: 1.01-2.34, p = 0.047).

CONCLUSIONS

The CXI may be a valuable prognostic tool for predicting survival outcomes in patients with u-HCC receiving Atez/Bev.

Для цитирования: Nguyen Khanh Van, Matsui Kosuke, Kosaka Hisashi, Matsushima Hideyuki, Yamamoto Hidekazu, Lai Tung Thanh, Inoue Kyoko, Takada Moriyasu, Tada Fujimasa, Hiraoka Atsushi, Hatanaka Takeshi, Tada Toshifumi, Kumada Takashi, Kato Hiroki, Yoshii Kengo, Yamaguchi Takashi, Shimoda Shinji, Naganuma Makoto, Kaibori Masaki. Cachexia Index as a Prognostic Indicator in Patients with Unresectable Hepatocellular Carcinoma Receiving Atezolizumab and Bevacizumab Therapy.. Oncology. 2025. DOI: 10.1159/000544979.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.